3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
3
Phase 4
1
Phase 3
1
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Breast Neoplasms
16
Triple Negative Breast Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Neoplasm Metastasis
2
Melanoma
2
Leukemia, Myeloid, Acute
2
Head and Neck Neoplasms
2
Endometrial Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Breast Diseases
2
Uterine Cervical Neoplasms
1
Solid Tumors Refractory to Standard Therapy
1
Solid Tumors
1
Solid Tumor, Adult
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Neoplasms
1
Liposarcoma, Myxoid
1
Liposarcoma
1
Kidney Neoplasms
1
Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
1
Hereditary Sensory and Autonomic Neuropathies
1
HER2-positive Breast Cancer
1
Glioblastoma
1
Gastrointestinal Neoplasms
1
Fallopian Tube Neoplasms
1
Esophageal Neoplasms
1
ER+ HER2- Advanced Breast Cancer
1
Interventions
pembrolizumab
36
Nivolumab
32
Bevacizumab
13
Sunitinib
10
Ipilimumab
10
aldesleukin
7
Interleukin-2
7
Axitinib
7
lenvatinib
6
cabozantinib
6
Paclitaxel
6
Everolimus
6
Docetaxel
6
Cyclosporine
6
Cyclophosphamide
6
fludarabine phosphate
5
Sorafenib
5
Radiotherapy
5
Peripheral Blood Stem Cell Transplantation
5
Mycophenolic Acid
5
fludarabine
4
cemiplimab
4
belzutifan
4
Whole-Body Irradiation
4
Radiosurgery
4
Interferon-alpha
4
Cetuximab
4
durvalumab
3
bempegaldesleukin
3
avelumab
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Carcinoma, Renal Cell
×
palbociclib
×
Clear all
NCT05468697
2026-01-23
MK-6482-024
Merck Sharp & Dohme LLC
Phase 1/2
Active not recruiting
60 enrolled